Want to see JP:2370 full AI Analyst Report?
2370 Stock Chart & Stats
¥29.00
-¥1.00(-2.70%)
At close: 4:00 PM EST
¥29.00
-¥1.00(-2.70%)
Day’s Range― - ―
52-Week Range¥23.00 - ¥43.00
Previous CloseN/A
Volume258.10K
Average Volume (3M)1.57M
Market Cap
¥7.35B
Enterprise Value¥3.72K
Total Cash (Recent Filing)¥5.03B
Total Debt (Recent Filing)¥91.32M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.29
Shares Outstanding282,667,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.11
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company’s effectively zero debt profile materially reduces near-term solvency risk and preserves financial flexibility. Over the next several months this supports the ability to fund operations, pursue client contracts or restructure financing without pressure from interest costs or covenant constraints.
Revenue GrowthRecent top-line growth (11.8% in FY2025 and positive revenue growth trend) signals sustained client demand for clinical research services. Durable revenue expansion helps spread fixed costs, supports scale benefits and creates a foundation to improve margins if operational efficiency initiatives stick.
Outsourced Clinical Services ModelMEDINET operates in the structurally growing market for outsourced clinical and life-science research services. Fee-based, contract-driven work for pharma and institutions is sticky and expertise-intensive, supporting recurring revenue potential and client relationships that persist beyond short-term cycles.
Bears Say
Severe Cash BurnPersistent negative operating and free cash flow means reported losses translate into real liquidity outflows, eroding runway. Over a multi-month horizon this raises the likelihood of needing external financing, which can dilute shareholders or constrain investment in operational improvements.
Large Persistent LossesVery large operating and net losses indicate an unresolved structural profitability issue. Continued negative margins undermine internal funding for growth, increase reliance on external capital, and create uncertainty about the company’s ability to achieve sustainable positive earnings within the medium term.
Declining Shareholder EquityMaterial erosion of equity over recent years reflects cumulative losses and weak returns on capital, reducing the company’s buffer against shocks. Lower equity limits balance sheet capacity to absorb setbacks and may increase pressure to raise capital under less favorable terms if performance does not improve.
MEDINET Co., Ltd. News
2370 FAQ
What was MEDINET Co., Ltd.’s price range in the past 12 months?
MEDINET Co., Ltd. lowest stock price was ¥23.00 and its highest was ¥43.00 in the past 12 months.
What is MEDINET Co., Ltd.’s market cap?
MEDINET Co., Ltd.’s market cap is ¥7.35B.
When is MEDINET Co., Ltd.’s upcoming earnings report date?
MEDINET Co., Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 79 days.
How were MEDINET Co., Ltd.’s earnings last quarter?
MEDINET Co., Ltd. released its earnings results on Aug 13, 2026. The company reported -¥1.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MEDINET Co., Ltd. overvalued?
According to Wall Street analysts MEDINET Co., Ltd.’s price is currently Overvalued.
Does MEDINET Co., Ltd. pay dividends?
MEDINET Co., Ltd. does not currently pay dividends.
What is MEDINET Co., Ltd.’s EPS estimate?
MEDINET Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDINET Co., Ltd. have?
MEDINET Co., Ltd. has 282,667,330 shares outstanding.
What happened to MEDINET Co., Ltd.’s price movement after its last earnings report?
MEDINET Co., Ltd. reported an EPS of -¥1.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4%.
Which hedge fund is a major shareholder of MEDINET Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2370
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MEDINET Co., Ltd.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
Technical Analysis
Linical Co., Ltd.
―
Trans Genic Inc.
―
Soiken Holdings Inc.
―
―
PRISM BioLab Co. LTD
―